May 4, 2020

Dear Colleague:

The Prescription Drug User Fee Amendments of 2017 (PDUFA VI) amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizing the Food and Drug Administration (FDA or Agency) to assess and collect two types of user fees – human drug application fees and prescription drug program fees (program fees). Under PDUFA VI, a program fee is assessed annually for each prescription drug product identified in an approved human drug application, with a maximum of five program fees assessed for a single approved application.¹ ²

FDA will issue the fiscal year (FY) 2021³ program fee invoices for PDUFA fee-eligible products⁴ in August 2020.⁵ To prepare the FY 2021 invoices, we ask for your assistance in confirming or correcting your company’s contact information and the PDUFA program fee-eligible products according to the instructions below. Please submit your response by Monday, June 1, 2020.

I. Review Your Company’s Contact Information and Products List

Attachment A – Company Contact Information

Attachment A contains the contact information FDA has on file for the person designated by your company to receive correspondences, invoices, and inquiries concerning prescription drug user fees. Please review and make corrections on Attachment A or confirm that the information is correct as listed and return the signed form by email to the PDUFA User Fee staff at CDER Collections@fda.hhs.gov.

Attachment B – Product List

Attachment B contains a list of the products that are currently liable for the FY 2021 program fees. Please review your existing product list, cross out any products that you believe should not be assessed a program fee, and include the reason why it should not be assessed a fee (e.g., generic competition, revocation, or discontinuation of a product).

¹ Section 736(a)(2)(A) of the FD&C Act.
² Section 736(a)(2)(C) of the FD&C Act.
³ FY 2021 = October 1, 2020, through September 30, 2021.
⁴ Prescription drug products listed in the active section of the Orange Book and the CDER/CBER Billable Biologic Lists as of October 1, 2020.
⁵ The FY 2021 fees will be published in a Federal Register notice in August 2020.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
If any product is omitted that should be included on the existing product list, please add the relevant product information on the “Missing PDUFA Eligible Products List” page and include the reason why it should be assessed a fee. Please make your changes directly on the lists provided in Attachment B rather than creating a separate list.

II. Confirm Your NDA Prescription Drug Products in the Orange Book

A list of user fee-eligible prescription drug products for which the Center for Drug Evaluation and Research (CDER) has regulatory responsibility can be found in the “Prescription Drug Product List” of the Orange Book, available at https://www.accessdata.fda.gov/scripts/cder/ob/.

After making any necessary updates to the list of your products in Attachment B, we recommend reviewing your company’s current list of drug products in the Orange Book and notifying the Agency if your product is being discontinued or withdrawn from sale. The applicant should submit a notification of withdrawal from sale in a letter to the applicable NDA file through the electronic submissions gateway. The notification should prominently identify the submission as an “ADMINISTRATIVE CHANGE / NOT AVAILABLE FOR SALE.” NDA holders are required to provide a written notification to FDA 180 days prior (or as practicable) to withdrawing an approved drug product for sale. For FY 2021 invoices, such submission should be submitted no later than June 30, 2020. A courtesy email notification regarding your product marketing status change should be sent to CDERCollections@fda.hhs.gov.

If you submit a drug product’s marketing status change after June 30, 2020, or if the drug product’s marketing status is not reflected in Orange Book June Cumulative Supplement update, the product may be included on your FY 2021 invoice. You may be eligible for a refund of the assessed program fee provided you submit the drug product’s marketing status change.

---

6 The FDA Reauthorization Act of 2017 added section 506I to the FD&C Act requiring application holders to notify the FDA of the marketing status of drug products approved under such applications.

7 The electronic submissions gateway is available at https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/. Questions related to electronic submissions should be emailed to the CDER Electronic Submission (ESUB) Team at esub@fda.hhs.gov.


9 The Agency may verify marketing status by requesting information from the applicant including: (1) the date on which the drug is expected to no longer be available for sale; (2) the last date of distribution of the drug product; (3) the last manufacturing date of the final dosage form of the drug product with lot numbers; (4) expiration dates.

10 We note that there may be user fee implications associated with moves to and from the discontinued section. We also note that a routine, temporary interruption in the manufacturing, supplying, and distribution of a product or a request that may be made to circumvent the annual invoicing process is generally not considered a withdrawal from sale.

11 Section 506I of the FD&C Act requires NDA holders to provide written notification to FDA 180 days prior to withdrawing an approved product from sale, or as soon as practicable, but no later than the date of withdrawal.
status change to the applicable NDA no later than **September 30, 2020**. To be eligible for a refund, you must submit a refund request in writing to the User Fee staff at CDERCollections@fda.hhs.gov no later than 180 days after the fee is due.12

Failure to move a product to the Discontinued Drug Product List of the Orange Book could result in the assessment of fees, even if the product is not marketed.

**III. Confirm Your Biological Products on the CDER and CBER Lists**

For a current list of user fee-eligible licensed therapeutic biological products for which **CDER** has regulatory responsibility, please see the *CDER Billable Biologic List* at https://www.fda.gov/media/76650/download.

For a current list of user fee-eligible licensed biological products for which the **Center for Biologics Evaluation and Research (CBER)** has regulatory responsibility, please see CBER’s list of *User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act (CBER Billable Biologic List)* at https://www.fda.gov/media/113210/download.

We recommend reviewing the information on both websites to obtain a complete list of your biological products. If you are no longer marketing a biological product and have delisted it under section 510 of the FD&C Act (21 U.S.C. 360), but the product is on the CDER or CBER Billable Biologic List, please notify FDA by **June 30, 2020**:

- For **CDER** regulated biological products, contact the CDER User Fee staff at CDERCollections@fda.hhs.gov and request in writing that FDA move the product to the **CDER Discontinued Product List**.

- For **CBER** regulated biological products, submit a Product Correspondence to the Product Review Office requesting that the product be moved to the **CBER Discontinued Products List** and copy the CBER User Fee staff at CBERPDUFAstaff@fda.hhs.gov. Please include CDERCollections@fda.hhs.gov on correspondences sent to the CBER User Fee staff.

If you notify the User Fee staff about the discontinuation of a biological product after June 30, 2020, the product may be included on the invoice issued in August. However, you may be eligible for a refund of the program fee(s) provided the User Fee staff receives notification to move the product to the Discontinued Product List no later than **September 30, 2020**. Please note that to be eligible for a refund, you must submit the refund request in writing to the User Fee staff **no later than 180 days** after the fee is due.13

---

12 Section 736(i) of the FD&C Act (21 U.S.C. 379h(i)).
13 Section 736(i) of the FD&C Act (21 U.S.C. 379h(i)).
Failure to move a product to the Discontinued Product List could result in the assessment of a program fee, even if the product is not marketed. If you plan to resume marketing your biological product and it is on the Discontinued Product List, you should notify the User Fee staff so the product can be moved to the appropriate CDER or CBER Billable Biologic List.

IV. How to Provide the Requested Information

Please return Attachments A and B (including the updated product list) no later than June 1, 2020, by email to the Prescription Drug User Fee staff at CDERCollections@fda.hhs.gov.

If you have any questions, please contact us by email at CDERCollections@fda.hhs.gov.

Sincerely,

Jeen Min, R.Ph.
CDR, United States Public Health Service
Branch Chief, Division of User Fee Management & Budget Formulation
Office of Management
Center for Drug Evaluation and Research

Attachments:
Attachment A – Company Contact Information
Attachment B – Lists of Products subject to user fees